PDCD1 and neoplasm: Lenvatinib, a tyrosine kinase inhibitor that selectively inhibits VEGFRs 1–3, FGFRs 1–4, platelet-derived growth factor receptor α, RET, and KIT [73,74], was found to enhance the anti-tumor response of anti-PD-1 blockade in preclinical models [75,76].